Zobrazeno 1 - 10
of 33
pro vyhledávání: '"O'Donnell EK"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US. catheriner_marinac@dfci.harvard.edu.; Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US. catheriner_marinac@dfci.harvard.edu., Downey K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US., Perry J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US., Fisher-Longden B; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US., Rebbeck TR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.; Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US.; Zhu Family Center for Global Cancer Prevention, Harvard T.H. Chan School of Public Health, Boston, MA, US., Shah UA; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, US., O'Donnell EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.; Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.; Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.; Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US., Egleston BL; Fox Chase Cancer Center, Philadelphia, PA, US.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Oct 14; Vol. 14 (1), pp. 175. Date of Electronic Publication: 2024 Oct 14.
Autor:
O'Donnell EK; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA. Electronic address: Elizabeth_odonnell@dfci.harvard.edu., Borden BA; Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA., Ghobrial IM; Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02115, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
Publikováno v:
Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2024 Aug; Vol. 38 (4), pp. 743-753. Date of Electronic Publication: 2024 May 09.
Autor:
O'Donnell EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Harvard Medical School, Boston, MA 02215, USA. Electronic address: elizabeth_odonnell@dfci.harvard.edu.
Publikováno v:
Hematology/oncology clinics of North America [Hematol Oncol Clin North Am] 2024 Aug; Vol. 38 (4), pp. xi-xii. Date of Electronic Publication: 2024 May 07.
Autor:
Lee DJ; Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., O'Donnell EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, United States., Raje N; Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Panaroni C; Department of Medicine, Massachusetts General Hospital, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Redd R; Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, United States., Ligibel J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States., Sears DD; College of Health Solutions, Arizona State University, Phoenix, AZ, United States., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, United States., Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, United States., Marinac CR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.; Harvard Medical School, Boston, MA, United States.; Center for Early Detection and Interception of Blood Cancers, Dana-Farber Cancer Institute, Boston, MA, United States.
Publikováno v:
JMIR research protocols [JMIR Res Protoc] 2024 Mar 11; Vol. 13, pp. e51368. Date of Electronic Publication: 2024 Mar 11.
Autor:
Midha S; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Hartley-Brown MA; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Mo CC; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA., Hossain S; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA., Nadeem O; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA., O'Donnell EK; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Bianchi G; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Sperling AS; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.; Division of Hematology, Brigham and Women's Hospital, Boston, MA, USA., Laubach JP; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA., Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Jerome Lipper Center for Multiple Myeloma Research, Harvard Medical School, Boston, MA, USA.
Publikováno v:
Expert opinion on drug safety [Expert Opin Drug Saf] 2023 Jul-Dec; Vol. 22 (11), pp. 1049-1071. Date of Electronic Publication: 2023 Nov 28.
Autor:
Mo CC; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA., Yee AJ; Massachusetts General Cancer Center Harvard Medical School Boston Massachusetts USA., Midha S; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.; Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA., Hartley-Brown MA; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.; Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA., Nadeem O; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA., O'Donnell EK; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.; Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA., Bianchi G; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.; Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA., Sperling AS; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.; Division of Hematology Brigham and Women's Hospital Boston Massachusetts USA., Laubach JP; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA., Richardson PG; Department of Medical Oncology Dana-Farber Cancer Institute Jerome Lipper Center for Multiple Myeloma Research Harvard Medical School Boston Massachusetts USA.
Publikováno v:
EJHaem [EJHaem] 2023 May 15; Vol. 4 (3), pp. 792-810. Date of Electronic Publication: 2023 May 15 (Print Publication: 2023).
Autor:
Frigault MJ; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Bishop MR; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL., Rosenblatt J; Beth Israel Deaconess Medical Center, Boston, MA., O'Donnell EK; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Raje N; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Cook D; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Logan E; Beth Israel Deaconess Medical Center, Boston, MA., Avigan DE; Beth Israel Deaconess Medical Center, Boston, MA., Jakubowiak A; David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL., Shaw K; Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA., Daley H; Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA., Nikiforow S; Dana Farber Cancer Institute, Cell Manipulation Core Facility, Brookline, MA., Griffin F; Arcellx, Inc., Gaithersburg, MD., Cornwell C; Arcellx, Inc., Gaithersburg, MD., Shen A; Arcellx, Inc., Gaithersburg, MD., Heery C; Arcellx, Inc., Gaithersburg, MD., Maus MV; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2023 Mar 14; Vol. 7 (5), pp. 768-777.
Autor:
Miller KC; Department of Medicine, Massachusetts General Hospital, Boston, MA, USA., Johnson PC; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA.; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital, Boston, MA, USA., Yee AJ; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., Branagan AR; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., O'Donnell EK; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA., Saucier A; Tufts University School of Medicine, Boston, MA, USA., Jacobson CA; Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute, Boston, MA, USA., Frigault MJ; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Raje NS; Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, MA, USA. nraje@mgh.harvard.edu.; Center for Multiple Myeloma, Massachusetts General Hospital, Boston, MA, USA. nraje@mgh.harvard.edu.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2022 Nov 01; Vol. 12 (10), pp. 146. Date of Electronic Publication: 2022 Nov 01.
Autor:
O'Donnell EK; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Shapiro YN; Massachusetts General Hospital Cancer Center, Boston, MA., Yee AJ; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.; Mass General/North Shore Cancer Center, Danvers, MA., Nadeem O; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Laubach JP; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Branagan AR; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., Anderson KC; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Mo CC; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Munshi NC; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Ghobrial IM; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Sperling AS; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and.; Brigham and Women's Hospital, Boston, MA., Agyemang EA; Massachusetts General Hospital Cancer Center, Boston, MA., Burke JN; Massachusetts General Hospital Cancer Center, Boston, MA., Harrington CC; Massachusetts General Hospital Cancer Center, Boston, MA., Hu BY; Massachusetts General Hospital Cancer Center, Boston, MA., Richardson PG; Harvard Medical School, Boston, MA.; Dana-Farber Cancer Institute, Boston, MA; and., Raje NS; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA., El-Jawahri A; Massachusetts General Hospital Cancer Center, Boston, MA.; Harvard Medical School, Boston, MA.
Publikováno v:
Blood advances [Blood Adv] 2022 Sep 13; Vol. 6 (17), pp. 4967-4974.